Comparison of erythromycin ethyl succinate, stearate and estolate treatments of group A streptococcal infections of the upper respiratory tract.
The microbiologic and clinical responses of acute Group A beta-hemolytic streptococcal infections of the upper respiratory tract to oral treatment with erythromycin ethyl succinate, stearate, and estolate were studied in 303 patients. Streptococcal M and T typing was done on all positive cultures. The overall cure rate was 95.4 per cent, with no statistically significant differences in clearing organisms from the pharynx. Of the 285 cured patients who completed the prescribed follow-up period, 11 had recurrences between the 12th and 31st day after initiation of therapy, and five developed new infections. No cases of rheumatic fever or glomerulonephritis were encountered during a follow-up study. Eight gastrointestinal reactions and one transient rash occurred. Results with these forms of erythromycin compare favorably with published results for similar infections treated with oral penicillins.
D000284:Administration, Oral; D002648:Child; D002675:Child, Preschool; D004917:Erythromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004918:Erythromycin Estolate / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D010406:Penicillins / Q000627:therapeutic use; D012008:Recurrence; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013228:Stearates / Q000494:pharmacology / Q000627:therapeutic use; D013290:Streptococcal Infections / Q000188:drug therapy*; D013297:Streptococcus pyogenes / Q000187:drug effects; D013386:Succinates / Q000494:pharmacology / Q000627:therapeutic use
D010406:Penicillins; D013228:Stearates; D013386:Succinates; D004917:Erythromycin; D004918:Erythromycin Estolate